Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014

Diabetes Therapy

Volumn 8, Issue 4, 2017, Pages 863-873

  Carls, Ginger ^a   Huynh, Johnny ^a   Tuttle, Edward ^a   Yee, John ^b   Edelman, Steven V ^b,c,d  

^a ANALYSIS GROUP   (United States)

^b Research Triangle   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Taking Control of Your Diabetes   (United States)

Author keywords

Diabetes; Glycemic control; Trends; United States

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C;

ADULT; AGE; ARTICLE; BODY MASS; COMORBIDITY; CONSERVATIVE TREATMENT; DIABETES MELLITUS; EDUCATION; GLYCEMIC CONTROL; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MIDDLE AGED; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREND STUDY;

EID: 85027008044     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-017-0280-5     Document Type: Article

References (23)

1. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in US diabetes care, 1999–2010. N Engl J Med. 2013;368(17):1613–24.
2. Centers for Disease Control and Prevention. Number (in Millions) of Civilian, Non-Institutionalized Persons with Diagnosed Diabetes, US, 1980–2014; 2015. http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm. Accessed Dec 1.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–79.
4. National Quality Forum. Comprehensive diabetes care: Hemoglobin A1c (HbA1c) poor control (>9.0%) Washington, DC; 2014. http://www.qualityforum.org. Accessed Sept 1.
5. National Committee for Quality Assurance. The State of Health Care Quality 2015; 2015.
6. Centers for Medicare and Medicaid Services (CMS). Medicare 2015 Part C and D star rating technical notes; 2015.
7. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.
8. American Diabetes A. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34(Suppl 1):S11–61.
9. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2016. http://www.cdc.gov/nchs/nhanes/index.htm. Accessed 5 May 2017.
10. Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the US, 2014. Atlanta: US Department of Health and Human Services; 2014.
11. Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care. 2017;40(4):468–75.
12. Claxton G, Raw M, Long M, Panchal N, Damico A. Employer health benefits 2015 annual survey. The Kaiser Family Foundation and Health Research and Educational Trust; 2015.
13. Tang KL, Barnieh L, Mann B, et al. A systematic review of value-based insurance design in chronic diseases. Am J Manag Care. 2014;20(6):e229–41.
14. Berkowitz SA, Meigs JB, Wexler DJ. Age at type 2 diabetes onset and glycaemic control: results from the National Health and Nutrition Examination Survey (NHANES) 2005–2010. Diabetologia. 2013;56(12):2593–600.
15. Ali MK, Bullard K, Imperatore G, Barker L, Gregg EW. Characteristics associated with poor glycemic control among adults with self-reported diagnosed diabetes—National Health and Nutrition Examination Survey, US, 2007–2010. Morb Mortal Wkly Rep. 2012;61(2):32–7.
16. Dwyer-Lindgren L, Mackenbach JP, van Lenthe FJ, Flaxman AD, Mokdad AH. Diagnosed and undiagnosed diabetes prevalence by county in the US, 1999–2012. Diabetes Care. 2016;39:1556–62.
17. Farr AM, Sheehan JJ, Curkendall SM, Smith DM, Johnston SS, Kalsekar I. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. Adv Ther. 2014;31(12):1287–305.
18. Buysman EK, Liu F, Hammer M, Langer J. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. Adv Ther. 2015;32(4):341–55.
19. Ta JT, Erickson SC, Qiu WA, Patel BV. Is there a relationship between Part D medication adherence and part c intermediate outcomes star ratings measures? J Manag Care Spec Pharm. 2016;22(7):787–95.
20. Erickson SC, Scott LR, Qui W, Patel BV. Adherence trends for 3 chronic disease medication classes among differently insured populations. Am J Pharm Benefits. 2014;6(1):32–7.
21. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther. 2011;33(1):74–109.
22. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Project Hope). 2011;30(1):91–9.
23. García-Pérez L-E, Álvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–94.